Phase III Study Evaluating the Efficacy and Safety of Canakinumab in Combination with Docetaxel vs Placebo in Combination with Docetaxel in Subjects with NSCLC
A randomized, double-blind, placebo-controlled trial of docetaxel with either canakinumab or a placebo dosed intravenously every 3 weeks in patients with NSCLC previously treated with PDL1 inhibitors and platinum based chemotherapy without success.
Determining hBD-3 as a valid biomarker in head and neck cancer
This is an umbrella study using tissue samples from consent to the UCCI-UMB-14-01 protocol. Oral saliva samples will be used to replicate the human beta defensin index's ability to distinguish oral squamous cell carcinoma(OSCC) from non-cancerous lesions.